Systemic Candidiasis and Systemic Mycoses

Systemic Candidiasis

Risk factors: breached barriers (CVC, abdominal surgery, burns), disrupted flora (broad-spectrum antibiotics), immunosuppression (neutropenia, chemo, transplant, steroids, HIV), critical illness (ICU stay, TPN, hemodialysis).

C. albicans = commonest overall. Non-albicans rising: C. tropicalis, C. glabrata, C. parapsilosis, C. auris (MDR, healthcare-associated) — varying azole susceptibility, affects empirical choice.

Clinical: Candidemia — asymptomatic OR nonspecific sepsis (indistinguishable from bacterial — diagnostic trap, under-suspected). Disseminated/invasive: Chorioretinitis (distinctive fundoscopic finding, screen ALL candidemia patients), Hepatosplenic candidiasis (post-neutropenia recovery, “bull’s-eye” imaging lesions), renal involvement, endocarditis (prosthetic valve/IVDU), meningitis.

Diagnosis: Blood culture = traditional reference standard, BUT sensitivity LIMITED (misses deep-organ disease without bloodstream seeding), slow (2-3 days). β-D-glucan: broad fungal marker, earlier/non-culture. NOT species-specific. UNRELIABLE for Cryptococcus/zygomycetes (see General Mycology). Mannan/anti-mannan Ab, PCR: additional non-culture options, used IN COMBINATION (no single test sufficient alone). Direct visualization (biopsy/aspirate, sterile site): valuable where accessible.

Treatment: Echinocandins (caspofungin, micafungin, anidulafungin) = FIRST-LINE for most invasive candidiasis (critically ill, neutropenic, azole-resistance concern). Fluconazole: stable patients, known/likely fluconazole-susceptible species. Amphotericin B (liposomal preferred): refractory cases, reduced-echinocandin-susceptibility species, CNS/ocular disease. Central line removal = CRITICAL adjunct (biofilm poorly cleared by antifungals alone).

Systemic (Endemic Dimorphic) Mycoses

Thermally dimorphic: mold(25°C, environment) ↔ yeast/spherule(37°C, body). Inhaled spores → pulmonary infection → disseminate regardless of immune status, but SEVERITY/dissemination risk ↑ sharply with ↓CMI (HIV/AIDS especially). Geographically restricted (diagnostic clue via travel/residence history).

Histoplasmosis (H. capsulatum): Ohio-Mississippi valleys USA, Latin America/Africa/Asia (incl. Indian river valleys). Linked: bird/bat dropping-enriched soil (caves, coops). Most = asymptomatic/mild flu-like. Progressive disseminated (hepatosplenomegaly, pancytopenia, mucocutaneous ulcers) = mainly immunocompromised (advanced HIV).

Blastomycosis (B. dermatitidis): Ohio-Mississippi valleys + Great Lakes USA, parts Africa. Pulmonary disease (mimics bacterial pneumonia/malignancy on imaging). NOTABLE: disseminates to skin (verrucous/ulcerative) + bone even in IMMUNOCOMPETENT hosts — distinguishes from other systemic mycoses (usually need immunosuppression to disseminate).

Coccidioidomycosis (C. immitis/posadasii): arid SW USA + Mexico/C./S. America (“Valley fever,” CA/AZ). Distinctive: large SPHERULES with ENDOSPORES (not budding yeast/hyphae). Most = subclinical/mild pulmonary. Severe/disseminated (skin, bone, MENINGITIS) + mortality ↑ in: Filipino/African ancestry, pregnancy (mechanism unclear).

Paracoccidioidomycosis (P. brasiliensis): Latin America only. STRIKING MALE predominance (estrogen inhibits mycelium→yeast transformation — mechanism SPECIFIC to this organism). Chronic pulmonary disease + characteristic mucocutaneous ulceration (oral/perioral).

Diagnosis (General)

Direct microscopy/histopath (KOH, PAS, GMS):

Histoplasma: small intracellular budding yeast
Blastomyces: BROAD-BASED budding yeast
Coccidioides: spherules with endospores
Paracoccidioides: “SHIP’S WHEEL”/mariner’s wheel multiple budding

Culture (SDA): definitive but SLOW (weeks). Coccidioides = LAB HAZARD, BSL-3 for mold-phase culture. Antigen detection (urine/serum): available for Histoplasma, rapid + disseminated disease monitoring. Serology (CF, immunodiffusion): supports diagnosis, correlates with severity/prognosis in some.

Treatment (General)

Mild self-limited pulmonary, immunocompetent: often NO treatment, observe. Progressive/severe/disseminated: Itraconazole (mild-moderate), Amphotericin B liposomal (severe/life-threatening, esp. CNS) → itraconazole to consolidate after initial ampho B. Duration: PROLONGED (months) — relapse risk if cut short.

Systemic Candidiasis

Risk Factors and Pathogenesis

Candida species — commensal yeasts of the gut, mouth, and vagina in health — cause invasive, bloodstream disease specifically when host defences are breached or overwhelmed. The recognized risk factors cluster around a few themes: breached physical barriers (central venous catheters, major abdominal surgery, severe burns), disrupted competing flora (broad-spectrum antibiotics), immunosuppression (neutropenia, chemotherapy, transplantation, corticosteroids, HIV/AIDS), and critical illness generally (prolonged ICU stay, total parenteral nutrition, haemodialysis). Candida albicans remains the single most common cause of candidemia overall, but non-albicans species — C. tropicalis, C. glabrata, C. parapsilosis, and increasingly the multidrug-resistant, healthcare-associated C. auris — now account for a substantial and growing share, with real implications for empirical antifungal choice, since these species vary considerably in azole susceptibility.

Clinical Manifestations

Candidemia (bloodstream infection alone) can be asymptomatic or present as nonspecific sepsis indistinguishable clinically from bacterial bloodstream infection — a genuine diagnostic trap, since it is easy to under-suspect fungal aetiology in a septic ICU patient. Disseminated/invasive candidiasis follows haematogenous seeding to distant organs: chorioretinitis (a distinctive, dilated fundoscopic finding, part of why ophthalmology screening is recommended in every candidemia patient), hepatosplenic candidiasis (classically in patients recovering from neutropenia, with characteristic “bull’s-eye” lesions on imaging), renal involvement, endocarditis (particularly on prosthetic valves or in IV drug users), and meningitis.

Laboratory Diagnosis

Blood culture remains the traditional reference standard but has real, well-recognized sensitivity limitations (missing a meaningful fraction of true invasive candidiasis, especially deep-organ disease without concurrent bloodstream seeding) and a slow turnaround (typically 2–3 days). β-D-glucan assay detects a fungal cell-wall component shared broadly across invasive fungal pathogens, offering earlier, non-culture-based detection — though it is not species-specific and (as noted under General Mycology) is unreliable for the fungi that lack or under-express this component (Cryptococcus, zygomycetes). Mannan/anti-mannan antibody assays and PCR offer further non-culture options, increasingly used together in combination to improve overall sensitivity, since no single test performs well enough alone. Direct visualization of yeast/pseudohyphae in a sterile-site specimen (biopsy, aspirate) remains valuable where accessible.

Treatment

Choice is stratified by clinical severity and local resistance data: echinocandins (caspofungin, micafungin, anidulafungin) are now first-line for most invasive candidiasis, especially in critically ill or neutropenic patients and where azole resistance is a concern, given their favourable safety profile and broad activity including against several azole-resistant strains. Fluconazole remains appropriate for clinically stable patients with a species known or likely to be fluconazole-susceptible. Amphotericin B (preferably liposomal, for reduced nephrotoxicity) is reserved for refractory cases, specific non-albicans species with reduced echinocandin susceptibility, or CNS/ocular disease where drug penetration is a concern. Central line removal is a critical adjunct wherever a catheter is a plausible source, since biofilm-embedded organisms are poorly cleared by antifungals alone.

Systemic (Endemic Dimorphic) Mycoses

These are caused by thermally dimorphic fungi — organisms that grow as a mould in the environment (25°C) and convert to a yeast (or yeast-like spherule) form at body temperature (37°C) — acquired by inhaling spores from soil or environmental sources, establishing initial pulmonary infection, and capable of disseminating from there regardless of the host’s immune status, though disease severity and dissemination risk both rise sharply with impaired cell-mediated immunity (HIV/AIDS above all). Each has a geographically restricted natural range, which is itself a useful diagnostic clue when travel/residence history is taken properly.

Histoplasmosis (Histoplasma capsulatum): endemic to the Ohio-Mississippi River valleys of the USA and parts of Latin America, Africa, and Asia (including river-valley regions of India), classically linked to soil enriched by bird or bat droppings (caves, chicken coops). Most infection is asymptomatic or a mild, self-limited flu-like illness; progressive disseminated histoplasmosis (hepatosplenomegaly, pancytopenia, mucocutaneous ulcers) occurs mainly in the immunocompromised, especially advanced HIV.

Blastomycosis (Blastomyces dermatitidis): endemic to the Ohio-Mississippi valleys and around the Great Lakes (USA), and parts of Africa. Presents as pulmonary disease (often mimicking bacterial pneumonia or malignancy on imaging) with a notable tendency to disseminate to skin (verrucous or ulcerative lesions) and bone even in apparently immunocompetent hosts — a real point of distinction from the other systemic mycoses, which more typically need immunosuppression to disseminate.

Coccidioidomycosis (Coccidioides immitis/posadasii): endemic to the arid southwestern USA and parts of Mexico/Central/South America (“Valley fever” in California/Arizona). Distinctive tissue morphology — large spherules containing endospores, rather than budding yeast or hyphae. Most infection is subclinical or a mild pulmonary illness; severe pulmonary disease, disseminated disease (skin, bone, and notably meningitis), and mortality are all disproportionately higher in specific ethnic groups (Filipino and African ancestry) and in pregnancy, for reasons not fully explained.

Paracoccidioidomycosis (Paracoccidioides brasiliensis): confined to Latin America, with a striking male predominance in symptomatic disease (attributed to oestrogen’s inhibitory effect on the fungus’s mycelium-to-yeast transformation, a mechanism genuinely specific to this organism among the systemic mycoses). Presents as chronic pulmonary disease with characteristic mucocutaneous ulceration, especially oral and perioral.

Laboratory Diagnosis (Systemic Mycoses, General Principles)

Direct microscopy and histopathology of sputum, BAL fluid, or tissue biopsy (KOH mount, PAS, or GMS stain) can demonstrate the characteristic yeast forms directly — small intracellular budding yeasts for Histoplasma, broad-based budding yeast for Blastomyces, spherules with endospores for Coccidioides, and the distinctive “ship’s wheel” (mariner’s wheel) multiple-budding pattern for Paracoccidioides. Culture on Sabouraud’s dextrose agar is definitive but slow (weeks) and, for Coccidioides specifically, carries a genuine laboratory-acquired-infection hazard requiring BSL-3 handling of mould-phase cultures. Antigen detection (urine/serum) is available for Histoplasma and useful for rapid diagnosis and monitoring, particularly in disseminated disease. Serology (complement fixation, immunodiffusion) supports diagnosis and, in some of these diseases, correlates with disease severity/prognosis.

Treatment (Systemic Mycoses, General Principles)

Mild, self-limited pulmonary disease in an immunocompetent host often needs no treatment beyond observation. Progressive, severe, or disseminated disease is treated with itraconazole for milder-to-moderate presentations, and amphotericin B (liposomal preferred) for severe or life-threatening disease, particularly with CNS involvement — with itraconazole often used to complete/consolidate therapy after an initial amphotericin B course. Duration is typically prolonged (months), reflecting these organisms’ tendency toward relapse if treatment is cut short.